Advanced search    

Search: authors:"George T Grossberg"

7 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease William James Deardorff, George T Grossberg Department of Psychiatry ... Grossberg 0 0 Department of Psychiatry, St Louis University School of Medicine , St Louis, MO , USA Currently available therapies for the treatment of Alzheimer's disease (AD) consist of cholinesterase

Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch

Grossberg 1 James E Galvin 7 Jeffrey L Cummings 5 6 Tillmann Krahnke 4 Christine Strohmaier 4 0 Alzheimer's Disease and Other Cognitive Disorders Unit, ICN, Hospital Clínic i Universitari, IDIBAPS

Phantom Limb Pain: Mechanisms and Treatment Approaches

Received 10 May 2011; Accepted 1 July 2011 Academic Editor: Bjorn A. Meyerson Copyright © 2011 Bishnu Subedi and George T. Grossberg. This is an open access article distributed under the Creative Commons

Critical appraisal and role of memantine extended-release in the management of Alzheimer’s disease

Critical appraisal and role of memantine extended-release in the management of Alzheimer’s disease Indrapal Singh, George T GrossbergDepartment of Neurology and Psychiatry, St Louis University School of Medicine, St Louis, MO, USAAbstract: Alzheimer’s disease (AD) is a progressive, degenerative brain disease. Currently available US FDA-approved pharmacological management options...

Circadian Rhythm Disturbances in Patients with Alzheimer's Disease: A Review

Medicine, St. Louis, MO 63104, USA Received 21 April 2010; Accepted 27 July 2010 Academic Editor: Ricardo Nitrini Copyright © 2010 Dawit A. Weldemichael and George T. Grossberg. This is an open access

The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors

Introduction Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer’s disease (AD). This study evaluated the efficacy, safety, and tolerability of a higher-dose, once-daily, extended-release formulation in patients with moderate-to-severe AD concurrently taking cholinesterase inhibitors. Methods In this 24-week, double-blind...

Trial Designs Likely to Meet Valid Long-Term Alzheimer's Disease Progression Effects: Learning from the Past, Preparing for the Future

. Industry, academic, and regulatory agency viewpoints were discussed, followed by robust audience participation. The session topic was introduced by George T. Grossberg (St. Louis University School of